Oncology Midterm #2 Flashcards
1
Q
Oncology Agents
A
Selectivity is incredibly important but the ability to only kill cancer cells is impossible.
Cytotoxic agents: kill cancer cells, first agents developed. Cause necrosis
Cytostatic agents: inhibit the growth of cancer cells. Less toxic. Cause apoptosis
2
Q
Carcinogenesis
A
- Under normal circumstances cells in the human body are under strict control in terms of growth and differentiation, which are stimulated by growth factors.
- apoptosis: organized and programmed cell death. Normal cell maintenance in healthy tissue
- Hallmark of cancer is uncontrolled growth of abnormal cells which consume nutrients and energy within the host, and the cancer cells lose their ability to perform their normal functions1
3
Q
Solid vs Liquid
A
solid tumors: cancer cells are located in solid tissues, not as responsive to radiation
liquid tumors: cells in the blood, responsive to radiation
4
Q
Oncogenes vs Tumor suppressor genes
A
Oncogenes: mutation that occurs in proto-oncogenes, which promote cancer. Regulate the communication between cells and their outside environment
Tumor suppressor genes: mutations occur in these genes these genes normally suppress cancer, and when mutated they lack the ability to “turn off” cancer
5
Q
Types of mutations
A
inherited germ line mutations, spontaneous point mutations, chromosomal rearrangements or augmentation of gene expression
6
Q
Chronic myelogenous leukemia (CML) mutation
A
bcr-abl translocation (oncogene), Philadelphia chromosome. Liquid tumor. gene rearrangement, part of chromosome 22 is translocated to chromosome 9 to turn on cell growth. Chromosome 9 gets longer and chromosome 22 gets shorter.
7
Q
Cell Cycle stages
A
somatic cell division through mitosis
G0: resting phase
G1: initial phase of mitosis; synthesis of enzymes required for DNA synthesis (about 20 hours)
S: DNA synthesis and replication of DNA (about 20 hours)
G2: synthesis of RNA, protein and formation of mitotic spindle for duplication of the cell (2-10 hours)
M: mitosis (1 hour) forming 2 daughter cells that are clones of the mother cell.
8
Q
Polytherapy
A
Combining drugs that work at different phases of the cell cycle for greater cell kill
Cell cycle specific drugs: anti-cancer drugs that are specific for a certain phase in the cell cylce.
Antimetabolites: damage cells in the S phase
Antimitotics: Damage cells in the M phase
9
Q
Metastasis
A
process by which cancer cells leave the location of the parent tumor and spread to distant sites.
Bloodstream and lymphatic system are the primary distributors.
Primary tumor must slough off enough cells to allow one to travel to another site.
Liver is common, highly perfused. Same with lung, brain and bone marrow.
Most cancer patients die from the consequences of metastatic lesions rather than the parent tumor.
10
Q
Circulating tumor cells (CTCs)
A
type of cell that is sloughed from the primary cancer tumor. Measurement is used as a prognostic factor and a diagnostic factor and they are considered biomarkers or surrogate markers.
11
Q
Chemotherapy as treatment
A
One of the four major forms: surgery, radiotherapy, biological (bone marrow transplantation or stem cell transplantation) and chemotherapy
Cancer cells are not “intelligent” but they are “adaptive”. They survive by clonal selection and they use many mechanisms to survive. This is why we use polytherapy in treatment of cancer. Single agent therapy may be successful in early stage hormone dependent cancers like breast and prostate.
12
Q
Premedications
A
Minimize the occurrence of side effects and hypersensitivity
H1 antagonist: diphenhydramine
H2 antagonist: ranitidine
Corticosteroids: dexamethasone
Antiemetics for N/V
13
Q
Drug Resistance
A
Occurs because not all cancer cells in a given tumor are exactly alike.
Clonal selection: the cells most sensitive to the initial drug dies but the resistant cells survive and continue to grow and replicate
Prostate cancer example: Androgen dependent cells and androgen independent cells. With hormone withdrawal kill all of the AD cells but leave the AI cells. Tumor returns containing mainly AI cells.
14
Q
Clinical trials:
A
Phase 1 focus on PK and dose-limiting toxicities (10-25 subjects).
Phase 2 focus on signs of efficacy (30 patients).
Phase 3 focuses on proof of efficacy and frequency of side effects (100’s or 1000’s subjects).
15
Q
Response criteria in early phase trials (Phase 1 and 2):
A
Complete response (CR): no sign of cancer 1 month after completion of therapy
Partial response (PR): reduced tumor size of 30% or more
Stable disease (SD): tumor size has not increased more than 20% and decreased less than 30%
Progression (P): tumor has grown by more than 20% and/or formation of new lesions
16
Q
Response criteria for final stage trials (phase 3)
A
Overall survival (OS): how much longer do patients survive on average. gold standard.
Progression free survival (PFS): how much longer patients survive without progression (worsening) of disease.
17
Q
Personnel:
A
surgical oncologists, radiation oncologists, hematologic oncologists (largely liquid tumor), medical oncologists (largely solid tumor), oncology pharmacists, oncology nurses, oncology histopathologists and geneticists. Oncology pharmacists should pay attention to drug interactions and combined toxicities.
18
Q
Incidence
A
Use American Cancer Society for incidence and mortality
Most common: breast cancer, colorectal cancer, lung cancer and prostate cancer
Most lethal cancers: esophageal, glioblastoma (type of brain cancer), liver and bile duct and pancreatic. Also very rare cancers have high mortality because it is hard to conduct clinical trials for new treatment.
19
Q
Hematopoeisis
A
the process by the blood cell components are produced in the body.
Different cell types are produced down different paths and can be stimulated or inhibited differently
20
Q
Amount of cell types in body
A
Humans normally have approximately 5 million RBCs, 150,000-400,000 platelets and 4,000-11,000 WBC (which are subdivided into different populations). Low numbers of WBC make them vulnerable to depletion and they are necessary to prevent infection.
21
Q
Formation of hematopoetic cells
A
Hemocytoblast forms all the different blood cell types. Leukocytes are white and include granulocytes and agranulocytes. Erythrocytes are red. Thrombocytes are platelets.
22
Q
RBCs (erythrocytes)
A
Primary function is oxygen transport, Very rich in the oxygen carrier hemoglobin
Production can be stimulated by low oxygen content in blood which is detected in the kidneys. The kidney stimulates secretion of erythropoietin (Epo) which increases RBC production
Life-span is 120 days
23
Q
WBC (leukocytes)
A
Primary function is to fight infection, and there are many subtypes
life-span is hours to several days or a weeks
Granulocytes and Agranulocytes
24
Q
Granulocytes:
A
have the appearance of granules in their cytoplasm.
Granules are packets of digestive enzymes. Three subtypes:
- Neutrophils: target bacteria and fungi and destroy these pathogens by phagocytosis
- Eosinophils: target parasites and involved in allergic inflammatory responses
- basophils: store histamine for release during inflammation response. Hives, anaphylaxis
25
Agranulocytes:
appear not to have granules. Three subtypes:
1. Lymphocytes: large subset of cell types that includes B cells, T cells and NK cells. More abundant in the lymphatic fluids than in blood.
2. Monocytes: similar role to neutrophils and capable of phagocytosis but can also present pieces of pathogens to T cells
3. Macrophages: monocytes that are in the tissue.
26
Lymphocyte T cells
A. Four types of T cells, just know that the T cell can recognize cancer cells through MHC and attack the cancer cells.
B. However, cancer cells over time have adapted a B7 protein to recognize T cells and inactivate the T cells (cancer cell survives). Interacts with CTLA4 on T cell
PD-L1 protein on the cancer cell can also interact with the T cell and inactivate the T-cell through PD-1 receptor on T cell.
C. Recent development of antibodies to prevent inactivation of the T cell by the cancer therapy. Called immunotherapy.
D. Ipilumumab: Yervoy. anti-CTLA4 mAb that prevents interaction of B7 with CTLA4. Approved for metastatic melanoma
E. Pembrolizumab: Keytruda. anti-PD1 mAb that prevents interaction of PD-L1 with PD-1.
27
Platelets:
very important in clot formation. Average life span 8-9 days. Not as big of a concern.
28
Neutropenia:
low levels of neutrophils
29
Leukopenia:
low level of leukocytes
30
Thrombocytopenia:
low levels of platelets. Not as big of a concern in therapy.
31
Anemia:
the condition of abnormally low functional hemoglobin. Usually has a low red blood cell count.
32
Polycythemia:
condition of abnormally high RBC which can occur with overdose of erythropoietin
33
DNA cross-linkers and alkylating agents
General mechanism: DNA is electron rich and these agents are electron poor, causing the interaction.
These agents are non-cell cycle specific
34
Platinum Agents
Cisplatin, carboplatin, oxaliplatin
35
Cisplatin: uses
lung cancer, testicular cancer, ovarian cancer, bladder cancer. IV only
36
Cisplatin: Dose
20-100 mg/m2 but dependent on disease and renal function. Hydration before and after therapy.
37
Cisplatin: MOA
reacts with DNA bases, especially nitrogen 7 of guanine. Cis geometry is essential for activity
38
Cisplatin Structure
39
Cisplatin: Toxicity
quite toxic. Includes nephrotoxicity, ototoxicity, myelosuppression (loss of WBC and usually neutrophils), severe N/V. Sodium thiosulfate can be administered to reduce nephrotoxicity. Amifostine can be used to reduce ototoxicity.
40
Cisplatin: ADME
High renal excretion predisposes to renal toxicity, this can impact other drugs that are excreted by the kidneys. Plasma half life less than 30 minutes.
41
Cisplatin: Distribution
Distribution: Outside cells with high chloride concentration cisplatin remains intact, and neutral and can penetrate cells. Once inside cells the chloride concentration drops and water molecules replace chloride atoms and this aquated form is charged and locked inside the cell.
Diluent: must be saline to prevent "aquation" reaction.
42
Carboplatin Structure and Class
Platinum. Paraplatin
43
Carboplatin: Uses
mainly for ovarian cancer (often with cyclophosphamide), also used in prostate cancer (with docetaxol) and lung cancer (with paclitaxel).
44
Carboplatin: MOA
Similar to cisplatin but chemically more stable and less active, also less toxic.
45
Carboplatin: Toxicity
Less toxic than cisplatin. Myelosuppression, nephrotoxicity, ototoxicity, N/V.
46
Carboplatin: ADME
Main route of excretion is renal. Longer half-life than cisplatin, 3 hours. For patients with renal impairment dosing is guided by creatinine clearance
47
Carboplatin: Dilution
Can be diluted with D5W or NS. So less reactive than cisplatin.
48
Oxaliplatin Class and Structure
Eloxatin. Platinum Agent
49
Oxaliplatin: Uses
mainly colorectal cancer.
FOLFOX regimen: folinic acid/fluorouracil/oxaliplatin
FOLFIRINOX regimen: folinic acid/fluorouracil/irinotecan/oxaliplatin. effective but highly toxic. More agents you combine the more risk for toxicity. Used in pancreatic cancer.
50
Oxaliplatin: MOA
Similar to cisplatin and carboplatin. More lipophilic so more penetration into tissues. The need for pre-hydration and evaluating renal function is less critical.
51
Oxaliplatin: toxicities
peripheral neuropathy (occurs in cisplatin and carbo as well but not the major toxicity). Unknown mechanism for peripheral neuropathy. Myelosuppression.
52
Oxaliplatin: ADME
Elimination largely renal. Longer half-life than cisplatin and carboplatin.
53
Oxaliplatin: Dilution
dilution of oxaliplatin should not include saline (chloride ions) or agents that make the solution alkaline. Chloride addition produces dichloro form which is more active and much more toxic
54
Pipeline Platinums
Picoplatin and Satraplatin have been studied but have failed in recent clinical trials. Very active but too toxic, compared to the agents on the market
55
Busulfan Structure and Class
Busulfex or Myleran. Methyl Sulfates.
56
Busulfan uses
mainly IV for myeloablation prior to bone marrow or stem cell transplantation for CML. Has been used in combination with cyclophosphamide (BuCy regimen). IV or PO. PO used for palliative treatment of CML.
57
Busulfan MOA
bifunctional and direct alkylator of DNA.
58
Busulfan: Toxicities
extreme myelosuppression, hepatotoxicity
59
Busulfan: ADME
lipophilic and can penetrate the CNS. PK monitoring of busulfan level is common and is the best way to deliver the most precise dose to the patient, in order to avoid seizures.
60
Treosulfan: structure, class
Methyl sulfates. approved in Europe but not the US
61
Treosulfan: Uses
historically for ovarian cancer but now being studied for myeloablatiion prior to allogenic stem cell transplantation, in place of busulfan. Potentially has no need to do PK monitoring.
62
Treosulfan: Toxicity
more polar than busulfan so less seizures due to lower CNS penetration. Similar toxicities otherwise.
63
Treosulfan: MOA
Alkylator that forms epoxides intramolecularly prior to reacting with DNA. Is also a more potent immunosuppressant than busulfan so it has the potential for replacing busulfan in allogeneic transplants.
64
Treosulfan: ADME
More polar than busulfan so less penetration into CNS.
65
Thio-triethylenephosphoramide
Thiotepa. methyl sulfate
66
Thio-triethylenephophoramide: uses
breast cancer, ovarian cancer, myeloablative agent prior to allogeneic and autologous stem cell transplantation. IV. Used for bladder cancer but administration is intravesical (directly into the bladder)
67
Thio-triethylenephophoramide: Mechanism
direct alkylator of DNA but more active following conversion to Tepa, the FMO enzyme is responsible for this conversion. Parent drug and metabolite are active, therefore not a prodrug. Tepa contains a double bonded oxygen instead of sulfur. Sites of DNA binding are any of the three-membered ring carbons.
68
Thio-triethylenephosphoramide: Toxicity
When given IV, severe myelosuppression, infections and N/V
69
Thio-triethylenephosphoramide: ADME
elimination half life is 2 hours and Tepa is nearly 20 hours. Both can penetrate the CNS and cause dizziness, headaches, etc. Most excretion is renal
70
Thio-triethylenephosphoramide: Dose
administered as initial dose followed by maintenance doses every 1-4 weeks. Delayed or slow response does not necessarily indicate a lack of effect. Increasing frequency of dosing causes increases toxicity.
71
Dacarbazine
DTIC. methyl sulfate
72
Dacarbazine: Uses
Hodgkin's lymphoma as part of ABVD regimen (adriamycin/bleomycin/vinblastine/dacarbazine). Also used for melanoma. IV only
73
Dacarbazine: Mechanism
prodrug following N-dealkylation by cytochrome P450, the molecule tautomerizes to the more reactive form which reacts with DNA, specifically the O-6 position on guanine. DNA attacks on the methyl group outside the two nitrogens. See mechanism.
74
Dacarbazine: Toxicities
Myelosuppression, hepatotoxicity (severe and may cause death), N/V
75
Dacarbazine: ADME
metabolized by liver CYP1A2, but nearly half the drug excreted unchanged
76
Other methyl sulfates
procarbazine and Temozolomide
77
Mechlorethamine
Nitrogen Mustard/alkylating agents. Mustargen.
Very old agent, initially was a chemical warfare agent
78
Mechlorethamine: uses
formerly for various leukemias but used less today because of better agents. Palliative treatment for late stage Hodgkin's lymphoma.
79
Mechlorethamine: Mechanisms
Binds to DNA after formation of reactive aziridine ring which is very electrophilic and is a 3 membered ring. Bifunctional activity because both ethyl chlorides are reactive and can bind DNA.
80
Mechlorethamine: toxicities
highly toxic, myelosuppression, severe N/V, severe vesicant (hits skin or lungs and causes severe blistering) and local toxicity if extravasation occurs (leakage of solution around vein), hepatotoxic, rare secondary cases of hemolytic anemia or leukemia many years later
81
Mechlorethamine: ADME
So reactive that it reacts with water and biomolecules very quickly after administration
82
Chlorambucil
Leukeran. Alkylating agents/Nitrogen Mustards.
83
Chlorambucil: Uses
chronic lymphocytic leukemia (CLL), lymphosarcoma, Hodgkin's lymphoma. Administered PO
84
Chlorambucil: Mechanism
Active intact but less active than mechlorethamine. The electrons on the aromatic nitrogen are not as basic and the formation of the aziridinium ion is slower. Must be activated by N-dealkylation to form the aziridine ion.
85
Chlorambucil: Toxicities
Myelosuppression, hepatotoxicity (patients with impaired liver function should be closely monitored). Several CNS toxicities including seizures, tremors, hallucinations because the drug is non-polar (lipophilic) and can enter the CNS
86
Chlorambucil: ADME
Beta oxidation (chain shortening) important form of metabolism, and the metabolite retains anti-tumor activity
87
Melphalen
Alkeran. Alkylating agents/nitrogen mustards
88
Melphalen: Uses
Multiple myeloma. Palliative treatment for non-resectable ovarian cancer. IV or PO
89
Melphalen: Mechanism
active intact but less active relative to mechlorethamine. The electrons on the aromatic nitrogen are not as basic and the formation of the aziridinium ion is slower. Higher polarity due to the Nitrogen group on the right is charged (designed to hopefully improve uptake through amino acid recognition but that didn't work). Need N-dealkylation before able to form the aziridinium ion.
90
Melphalen: Toxicities
Myelosuppression, hepatotoxicity and less severe N/V. Rarely see pulmonary fibrosis and interstitial pneumonitis. CNS toxicities are rare because the drug is polar and does not enter the brain well.
91
Cyclophosphamide
Cytoxan. Alkylating agents/nitrogen mustard.
92
Cyclophosphamide: Uses
lymphomas, leukemias, multiple myeloma, breast cancer, myeloablation prior to transplantation. Administered IV and PO occasionally.
93
Cyclophosphamide: Mechanism
phosphorous withdrawals electrons from N even stronger than chlorambucil. Prodrug, activated by P450 dealkylation to hydroxylate. The hydroxy group collapses forming the aldehyde which tautomerizes to eliminate acrolein and a phosphoramide mustard which is capable of forming an aziridine and reacting with DNA.
94
Cyclophosphamide: Toxicities
myelosuppression, hemorrhagic cystitis (bladder toxicity due to acrolein). CNS toxicities
Patients should be well hydrated to protect against bladder toxicity. MesNA can also be used because it concentrates in the urine, binds to and inactivates the acrolein.
95
Ifosfamide
Ifex. Alkylating agent/nitrogen mustard.
96
Ifosfamide: Uses
Mainly testicular cancer. IV
97
Ifosfamide: Mechanism
Prodrug with same bioactivation mechanism as cyclophosphamide
Toxicities: myelosuprression, nephrotoxicity, hemorrhagic cystitis (bladder toxicity), CNS toxicities. Need to well hydrate prior to administration due to metabolite. Enhanced CNS toxicity can induce a coma and even death
98
Ifosfamide: ADME
similar to cyclophosphamide but CYP metabolism is slower so higher doses are needed. Dose-dependent PK, renal excretion.
99
Ifosfamide: Minimizing Toxicity
Hydration and MesNA prior to therapy to reduce bladder toxicity. The sulfur agent N-acetylcystein (NAC) may provide protection from nephrotoxicity. There is no agent for protection against CNS toxicity
100
Lomustine
CeeNU. Alkylating agents, nitrosoureas.
101
Lomustine: Use
Brain cancer (glioblastoma), Hodgkin's lymphoma. Administered PO
102
Lomustine: Mechanism
Prodrug that ultimately forms a diazonium ion that reacts with DNA. Also reacts with proteins and RNA. Might have some G1 or S phase specificity.
103
Lomustine: toxicities
Myelosuppression, hepatotoxicity, pulmonary toxicity, seizures. Leukemias and myelodysplasias have occurred years later.
104
Lomustine: ADME
Non-polar (lipophilic) drug that can enter the CNS. This explains its efficacy and CNS toxicities. Levels in CSF can reach 50 times the levels in the blood.
105
Carmustine
BiCNU or BCNU. Alkylating Agents/Nitrosourea
106
Carmustine: Uses
brain cancer (glioblastoma), multiple myeloma, NHL. Administered IV
107
Carmustine: Mechanism
Similar to lomustine, but can lead to additional electrophiles.
108
Carmustine: Toxicities
Similar to lomustine; myelosuppression, hepatic toxicity, acute pulmonary toxicities (pulmonary fibrosis), seizures. Leukemias and myelodysplasias have occurred years later.
109
Carmustine: ADME
Very unstable and degrades quickly when added to aqueous solution. Like lomustine, it is a non-polar (lipophilic) drug that can enter the CNS. This explains its efficacy and CNS toxicities. Levels in CSF can reach 50 times the levels in the blood.
110
Bendamustine
Treanda. Fake nitrosourea but is an alkylating agent
111
Bendamustine: Uses
CLL, NHL. IV. Being studied for the treatment of rare sarcomas.
112
Bendamustine: Mechanism
Not actually a nitrosourea, instead is an alkylating of the nitrogen mustard type. It causes inter- and intra- strand crosslinks with DNA bases.
113
Bendamustine: Toxicities
Nausea, fatigue, vomiting, diarrhea, constipation, fever, loss of appetite, unintentional weight loss, headache, difficulty breathing, rashes. Immunosuppression is common. Low incidence of alopecia.
114
Bendamustine: ADME
metabolized by CYP450 and excreted renal.
115
Streptozocin
Zanosar. alkylating agent/nitrosourea
116
Streptozocin: uses
Pancreatic cancer. IV
117
Steptozocin: Mechanism
prodrug that ultimately forms a diazonium ion. Sugar moiety (glucopyranose) helps to target to pancreatic cell, and makes the drug more polar to offset CNS toxicities.
118
Streptozocin: Toxicities
N/V, renal toxicity rarely associated with diabetes insipidus, mild myelosuppression
119
Streptozocin: ADME
substantial excretion by the kidneys.
120
Streptomocin: CNS
drug is non-polar and does not penetrate CNS very well.
121
Antimetabolites: general concept
Cell Cycle Specific for S-phase
Antimetabolites mimic endogenous molecules and in many cases target enzymes are irreversibly inhibited.
122
Methotrexate
Trexall : folate analog of the antimetabolites.
123
Methotrexate: uses
metastatic breast cancer, epidermoid head and neck cancer, lung cancer (squamous cell), pancreatic cancer and in combination with other agents for late stage non-Hodgkin's lymphoma. IV, IM, PO
124
Methotrexate: Mechanism
mimics the vitamin folic acid and therefore inhibits the enzyme dihydrofolate reductase (DHFR). Binding to and inhibiting DHFR prevents reduction of folate to Methenyl tetrahydroflorate which is a two carbon donor to TS. Two structural changes between methotrexate and folic acid: methyl group on the amine and an NH3 group instead of double bonded oxygen.
125
Methotrexate: Toxicities
myelosuppression, hepatotoxicity, nephrotoxicity. Lipophilic molecule and some penetration into CNS with consequent toxicities
126
Methotrexate: ADME
Actively taken into cells by the reduced folate carrier (RFC1). Once inside cells the molecule is polyglutamated by FPGS which adds negative charges to trap the molecule inside the cell. Polyglutamates are removed prior to excretion by the kidneys.
127
Methotrexate: Overdose
Intentional high doses can be corrected by administration of leucovorin and is called a "leucovorin rescue". In the body leucovorin is easily converted to methenyl tetrahydrofolate thus eliminating the need for the folate cycle completely.
128
Methotrexate: Other uses
RA and psoriasis
129
Pemetrexed
: Alimta. Antimetabolite, folate analog
130
Pemetrexed: Uses
non-small cell lung cancer (non-squamous) in combination with cisplatin or gemcitabine. Also used for mesothelioma in combination with cisplatin. IV
131
Pemetrexed: Mechanism
Similar to methotrexate but inhibits folate cycle at 3 steps including DHFR, TS and GARFT.
132
Pemetrexed: Toxicities
myelosuppression, liver toxicity, renal toxicity, less CNS penetration compared to methotrexate.
133
Pemetrexed: ADME
uptake and polyglutamation similar to methotrexate but the enzyme but is an even better substrate for polyglutamation by FPGS and thus is trapped in target cells better than methotrexate.
134
Pralatrexate
Folotyn. Newer folate analog being studied for use in peripheral T-cell lymphoma. It appears to have superior tumor uptake and efficacy, but further trials are necessary
135
5-FU
Pyrimidine Analog, antimetabolite
136
5-FU: uses
metastatic breast cancer, colorectal cancer in FOLFOX (folinic acid/5-FU/oxaliplatin) and FOLFIRI regimen (folinic acid/5-FU/irinotecan). Folinic acid serves to potentiate the activity of 5-FU by stimulating the turnover of TS which is the target enzyme of 5-FU.
137
5-FU: Mechanism
prodrug and mimic of uracil that is initially converted to ribosyl form and then specifically inhibits thymidylate synthestase (TS). Normal mechanism is that dUMP interacts with methylene tetrahydrofolate through TS to form thymidine and dihydrofolate. With F-dUMP binding to TS is halted because the flourine atom is a poor leaving group, this leads to no production of thymidine and irreversible inactivation of TS
138
5-FU: Toxicities
myelosuppression, mucositis, diarrhea.
139
5-FU: ADME
elimination from plasma is about 10-15 minutes and about 20% of the dose is excreted unchanged in the urine.
140
5-FU: Polymorphic
a route of catabolic metabolism is by dihydropyrimidine dehydrogenase (DPD). Deficiency in the activity of this enzyme can lead to elevated levels of 5-FU and consequent toxicities. Female African Americans are more likely to be deficient. There is a genetic test available for determining DPD status of a patient.
141
Floxuridine
pyrimidine agent like 5-FU but the ribose sugar is already attached. One step away from 5-F-dUMP. Used for liver metastasis from GI cancers. Given slowly as intra-arterial infusion to limit toxicity, conversion to 5-FU and circumvent DPD issues.
142
Capecitabine
Xeloda. Pyrimidine Analogs, antimetabolites
143
Capecitabine: uses
metastatic breast cancer, colorectal cancer, pancreatic cancer, gastric cancer. PO
144
Capecitabine: Mechanism
prodrug of 5-FU, mimic of uracil that specifically inhibits TS. Breakdown to 5-FU exploits the fact that critical enzymes are preferentially located in tumors.
145
Capecitabine: toxicities
similar to 5-FU and hand-foot syndrome because the drug has increased levels in the skin of hands and feet.
146
Capecitabine: ADME
Can inhibit CYP2C9 and clinically relevant interaction can occur with warfarin and phenytoin.
147
Cytarabine
AraC. Antimetabolite/pyrimidine analog
148
Cytarabine: Uses
various leukemias: acute lymphocytic leukemia (ALL), non-lymphocytic leukemia, chronic myelocytic leukemia (CML), meningeal leukemia. IV or IT for meningeal leukemia
149
Cytarabine: Mechanism
Inhibitor of DNA polymerase. Sugar moiety is arabinose and can be inserted properly into DNA but cannot by reduced to the deoxy form by ribonucleotide reductase preventing DNA elongation. Fools body into thinking it is cytosine.
150
Cytarabine: Toxicities
Myelosuppression, mucositis, AraC syndrome (fever, myalgia, bone pain)
151
Cytarabine: ADME
excreted in urine.
152
Gemcitabine
Gemzar. Antimetabolites/pyrimidine analogs
153
Gemcitabine: uses
pancreatic, NSCLC with cisplatin, breast cancer with paclitaxel, ovarian with carboplatin. Synergistic effects with other agents.
154
Gemcitabine: mechanism
Difluorinated sugar similar to cytosine. Dual mechanism: inhibits ribonucletide reductase the enzyme that converts ribonucletides into deoxy-ribonucleotides and the second mechanism is that the triphosphate form (dGTp) competes with dCTP for incorporation into DNA.
155
Gemcitabine: Toxicity
myelosuppression, paresthesias (numbness and tingling) and severe rash
156
Gemcitabine: ADME
Elimination is renal and both gender and age dependent. Elimination decreases with age and if you are female.
157
6-Mercaptopurine
: Purinethol. Antimetabolite, purine analog
158
6-mercaptopurine
ALL and acute myelogenous leukemia. PO
159
6-mercaptopurine: Mechanism
mimic of hypoxanthine, the precursor of adenine and guanine and therefore inhibits de novo purine synthesis. Specifically competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribiosyltransferase (HGPRTase)
160
6-mercaptopurine: toxicities
Myelosuppression, hyperuricemia (can be reduced with hydration, alkanalization and xanthine oxidase inhibitors like allopurinol), hepatotoxitiy
161
6-mercaptopurine: ADME
patients with low TPMT activity are at increased risk for severe toxicity. Genotypic and phenotypic tests are available.
162
Thioguanine
Tabloid. Antimetabolite, purine analog
163
Thioguanine: Uses
Acute non-lymphocytic leukemia. PO
164
Thioguanine: Mechanism
competes with hypoxanthine and guanine for HGPRTase. Essentially competes for the synthesis of guanine nucleotides.
165
Thioguanine: Toxicities
myelosuppression, N/V, hepatotoxicity
166
Thioguanine: ADME
Rapid. Same TPMT issue as with mercaptopurine and cross-resistance is high in cancer cells between mercaptopurine and thioguanine.
167
Fludarabine
Fludara. Antimetabolite, purine analog
168
Fludarabine: Uses
Chronic lymphocytic leukemia (CLL). IV or PO
169
Fludarabine: Mechanism
Both the base and the sugar are chemically modified relative to normal adenosine. Base is fluorinated and the sugar is an arabinose. The triphosphorylated form of the drug inhibits DNA polymerase, DNA primase and ribonucleotide reductase. Phosphate group is cleaved before entering cell and then once inside the cell is added back on.
170
Fludarabine: Toxicities
myelosuppression, hemolytic anemia, CNS toxicities at high dose
171
Fludarabine: ADME
high renal excretions so use in caution in patients with renal impairment
172
Cladribine and Clofaribine
both are purine analogs used in leukemias. Cladribine along with myelosuppression can cause hemolytic anemia and CNS toxicities.
Clofaribine can cause tumor lysis syndrome (TLS) due to the rapid death of leukemia cells. This can lead to respiratory and cardio toxicity due to the rapid release of cytokines.
173
Topoisomerase
Topo I and II are very important in the process of DNA replication. Only two Topo I agents have been approved (irinotecan and topotecan)
174
Irinotecan
Camptothecins: Topo I Inhibitors - Cell cycle specific (S and G2)
175
Irinotecan: use
colorectal cancer as a component to FOLFIRI (folinic acid/5-FU/ininotecan) also in FOLFIRINOX for pancreatic cancer.
176
Irinotecan: Mechanism
prodrug of SN-38. Enzymatic hydrolysis by esterase enzymes convert it into SN-38, which is the molecule that binds reversibly in the ternary complex that includes DNA and Topo 1. More of the esterase enzymes are present in tumor tissues than plasma and liver
177
Irinotecan: toxicities
myelosuppression, severe and unpredictable diarrhea with neutropenia which can lead to sepsis and death
178
Irinotecan: ADME
Polymorphism in the elimination of SN-38 which is glucuronidated by UGT1A1. 7/7 polymorphisms express low levels of enzyme and have higher AUC compared to 6/6 genotypes. Commercial genetic assays exist for the UGT1A1 status
179
Topotecan
: Hycamtin Camptothecins: Topo I Inhibitors - Cell cycle specific (S and G2)
180
Topotecan: uses
SCLC and ovarian cancer. IV and PO
181
Topotecan: mechanism
not a prodrug and does not require activation. Binds directly to Topo I enzyme. Is NOT extensively glucuronidated like SN-38 and is therefore no complicating factor of UGT1A1.
182
Topotecan: toxicites
myelosuppression, thrombocytopenia, diarrhea, N/V, leukocytes.
183
Topotecan: ADME
closed lactone ring has to undergo hydrolysis to the open carboxylate form which is inactive. Co-administration of oral cyclosporine A can increase the AUC over 2 fold.
184
Doxorubicin
: Adriamycin. Anthracyclines: No cell cycle specific but S phase sensitive
185
Doxorubicin: uses
acute lympoblastic leukemia (ALL), acute myelogenous leukemia (AML), soft tissue and bone sarcomas, Wilm's tumor, neuroblastoma. Also for breast, ovarian, bladder, thyroid, gastric cancers and Hodgkin's lymphoma. IV
186
Doxorubicin: mechanism
intercalates into DNA and inhibits Topo II. Can also generate reactive oxygen species which contributes to its efficacy but also cardiotoxicity
187
Doxorubicin: Toxicity
myelosuppression, cardiotoxicity (CHF), N/V, alopecia, peripheral neuropathy
188
Doxorubicin: ADME
quick distribution, half life 30-40 hours
189
Doxorubicin: preventing cardiotoxicity
dexrazoxane can be used to minimize cardiotoxicity
190
Doxil
pegylated liposomal form of doxorubicin. Extravasation and cardiotoxicity are less than doxorubicin but it can cause palmar-plantar erythrodyesesthesia (hand-foot syndrome) due to a change in drug distribution.
191
Daunorubicin
: Cerubidine. Anthracyclines: No cell cycle specific but S phase sensitive
192
Danunorubicin; uses
remission induction for acute non-lymphocytic leukemia and acute lymphocytic leukemia. IV only
193
Daunorubicin: Mechanism
intercalates into DNA to inhibit Topo II. Can also generate reactive oxygen species.
194
Daunorubicin: toxicitie
similar to doxorubicin. myelosuppression, cardiotoxicity, N/V, alopecia, peripheral neuropathy
195
DaunoXome
: liposomal formulation that is less toxic and is used mainly for Kaposi's sarcoma associated with HIV
196
Idarubicin
: Idamycin. Anthracyclines: No cell cycle specific but S phase sensitive
197
Idarubicin: use
AML, metastatic breast cancer. IV
198
Idarubicin: mechanism
Intercalates into DNA and inhibits Topo II. Can also generate reactive oxygen species
199
Idarubicin: toxicity
myelosuppression, cardiotoxicity, N/V, alopecia, peripheral neuropathy
200
Idarubicin: ADME
quick distribution, half life 22 hours. Metabolites remain active and can contribute to cardiotoxicity
201
Etoposide
: VP-16. Podophyllotoxins
202
Etoposide: uses
SCLC, sarcomas (Kaposi's and Ewing's), testicular cancer, lymphomas, non-lymphocytic leukemia, glioblastoma multiforme (brain cancer). IV or PO
203
Etoposide: mechanism
binds to topo II, but does not possess a quinone moiety and therefore does not generate reactive oxygen species or cardiotoxicity.
204
Etoposide: toxicity
myelosuppression, N/V, alopecia, serious hypotension if given IV too quickly. Hydration is important to prevent renal and bladder toxicity. Caution with cisplatin
205
Etoposide: ADME
elimination through kidneys and bladder
206
Teniposide
: VM-26. Podophyllotoxins
207
Teniposide: use
Childhood acute lymphoblastic leukemia. IV
208
Teniposide: mechanism
similar to etoposide, binds to topo II but does not possess a quinone moiety and therefore does not generate reactive oxygen species or cardiotoxicity
209
Teniposide: toxicity
myelosuppression, mucositis, hypersensitivity, N/V, alopecia, potential hypotension if given IV too quickly.
210
Teniposide: ADME
less polar than etoposide and there is less renal secretion.
